Notice for Retifanlimab (Specialised Therapeutics Alim Pty Ltd)
Active ingredients
Retifanlimab
Date of review outcome
Lapse date
Type
Priority review
Indication
In combination with carboplatin and paclitaxel for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC
Therapeutic area
Oncology